Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Cyclic peptides
Reexamination Certificate
1995-06-01
2002-05-28
Borin, Michael (Department: 1631)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Cyclic peptides
C530S327000, C530S328000, C514S009100, C514S015800
Reexamination Certificate
active
06395873
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates generally to methods of treating thrombosis, and, more particularly, to such methods using, peptides.
The formation of a blood clot within a blood vessel, a process termed thrombosis, is a serious condition which can cause tissue damage and, if untreated, eventually death. Thrombotic formation is dependent upon platelet aggregation. The interaction of blood platelets with the endothelial surface of injured blood vessels and with other platelets is a major factor in the course of development of thrombi.
Various products for dissolving such clots are now available, such as asprin, dipyridamole and heparin. These products generally kill or remove platelets, which can eliminate the clot, but has the potential serious side effect of causing prolonged bleeding. Moreover, the effect of such products can only be reversed by new platelets being formed or provided.
Platelet aggregation is dependent upon the binding of fibrinogen and other serum proteins to the glycoprotein GP IIb/IIIa complex on the platelet plasma membrane. GP IIb/IIIa is a member of a large family of cell adhesion receptors known as integrins, many of which are known to recognize an Arg-Gly-Asp (RGD) tripeptide recognition sequence. Individual receptor specificity is determined by the conformation that the RGD sequence adopts in each individual ligand. Inhibition or GP IIb/IIIa receptor binding, and therefore of platelet aggregation, without inhibition of other cell adhesion receptcrs would be necessary for the prevention of coronary thrombosis.
There thus exists a need for a composition able to specifically inhibit the platelet aggregation receptor GP IIb/IIIa and to dissolve blood clots without removing or killing platelets and without causing detrimental side effects such as prolonged bleeding. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic moieties adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic moiety an adjacent positively charged moiety. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.
REFERENCES:
patent: 4517666 (1985-05-01), Hideo
patent: 4547489 (1985-10-01), Goldstein
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4605512 (1986-08-01), Schaller et al.
patent: 4614517 (1986-09-01), Ruoslahti et al.
patent: 4661111 (1987-04-01), Ruoslahti et al.
patent: 4661471 (1987-04-01), Hawiger et al.
patent: 4666884 (1987-05-01), Hawiger et al.
patent: 4683291 (1987-07-01), Zimmerman et al.
patent: 4789734 (1988-12-01), Pierschbacher et al.
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4857508 (1989-08-01), Adams et al.
patent: 4879313 (1989-11-01), Tjoeng et al.
patent: 4929601 (1990-05-01), Brunetti et al.
patent: 4943562 (1990-07-01), Jolles et al.
patent: 5023233 (1991-06-01), Nutt et al.
patent: 5037808 (1991-08-01), Adams et al.
patent: 5041380 (1991-08-01), Ruoslahti et al.
patent: 5066592 (1991-11-01), Huang et al.
patent: 5612311 (1997-03-01), Pierschbacher
patent: 5643872 (1997-07-01), Ali et al.
patent: 5648330 (1997-07-01), Pierschbacher et al.
patent: 6013625 (2000-01-01), Pierschbacher et al.
patent: 2000048 (1990-04-01), None
patent: 3831714 (1990-03-01), None
patent: 3841763 (1990-06-01), None
patent: 317053 (1988-05-01), None
patent: 0275748 (1988-07-01), None
patent: 314576 (1989-05-01), None
patent: 332523 (1989-09-01), None
patent: 338634 (1989-10-01), None
patent: 0341915 (1989-11-01), None
patent: 347931 (1989-12-01), None
patent: 368486 (1990-05-01), None
patent: 382451 (1990-08-01), None
patent: 410537 (1991-01-01), None
patent: 410539 (1991-01-01), None
patent: 410540 (1991-01-01), None
patent: 410541 (1991-01-01), None
patent: 2617170 (1988-12-01), None
patent: 2207922 (1989-02-01), None
patent: 1006217 (1989-01-01), None
patent: WO88/03151 (1988-05-01), None
patent: WO 89/00200 (1989-01-01), None
patent: WO89/00200 (1989-01-01), None
patent: WO89/04837 (1989-06-01), None
patent: WO 89/04837 (1989-06-01), None
patent: WO89/05155 (1989-06-01), None
patent: WO89/05150 (1989-07-01), None
patent: WO 89/05150 (1989-07-01), None
patent: WO89/07609 (1989-08-01), None
patent: WO 89/07609 (1989-08-01), None
patent: WO 90/00178 (1990-01-01), None
patent: WO90/00178 (1990-01-01), None
patent: WO90/02751 (1990-03-01), None
patent: WO 90/02751 (1990-03-01), None
patent: WO90/06943 (1990-06-01), None
patent: WO 90/06943 (1990-06-01), None
patent: WO90/14103 (1990-11-01), None
patent: WO 90/15620 (1990-12-01), None
patent: WO90/15620 (1990-12-01), None
patent: WO91/01331 (1991-02-01), None
patent: WO 91/01331 (1991-02-01), None
patent: WO91/04031 (1991-04-01), None
patent: WO91/15515 (1991-10-01), None
patent: WO 91/15515 (1991-10-01), None
patent: WO91/15516 (1991-10-01), None
patent: WO 91/15516 (1991-10-01), None
patent: WO 91/15516 (1992-03-01), None
patent: WO 92/17492 (1992-10-01), None
Degen et al. Biochemistry, 26, 6165-6177, Aug. 1987.*
Morinaga et al. Proc. Natl. Acad. Sci, USA, 80, 4604-4608, Aug. 1983.*
Pierschbacher et al., “RGD Sequences”, J. Biol. Chem. v. 262, No. 36, pp. 17294-17298.*
Kopple et al., “Conformations of Arg-Gly-Asp Containing Heterodetic Cyclic Peptides: Solution and Crystal Studies”,J.Am. Chem Soc.,114: 9615-9623 (1992).
Creighton, T.ProteinsW.H. Freeman & Co., p. 9, 1984.
Marx, J.,Science248:1491-1493 (1990).
Pierschbacher M, et al.,J. Biol. Chem.262:(26):17294-17298 (1987).
Dayoff, M.,Atlas of Protein Seq. and Struct.5:89-99 (1972).
Joubert, F. et al.,Biochim Biophys. Acta579:228-233 (1979).
Gan, Z. et al.,J. Biol. Chem.263(36):19827-19823 (1988).
Huang, T. et al.,J. Biol. Chem.262(33):16157-16163 (1987).
Toda, K. et al.,J. Cell Biol.105:3097-3104 (1987).
Gehlsen, K. et al.,J. Cell Biol.106:925-930 (1988).
Lash, J. et al.,Developmental Biology123:411-420 (1987).
Haverstich, D. et al.,Blood66(4):946-952 (1985).
Singer, I, et al.,J. Cell Biol.104:573-584 (1987).
Gehlsen et al.,J. Cell Biol.105:3097-3104 (1987).
Siebers et al.,Eur. J. Biochem.178:131-140 (1988).
Ruoslahti et al.,Cell44:517-518 (1986).
Ruoslahti et al.,Falk Symposium43:239-244 (1987).
Bodanszky,Principles of Peptide Synthesis217-222 (1984).
Pelton et al.,Proc. Natl. Acad. Sci. USA82:236-239 (1985).
Sakakibara et al.,BBA303:198-202 (1973).
Kaiser and Kezcy,Science223:249-255 (1984).
Ohsaku et al.,Int. J. Biol. Macromol.6:234-240 (1984).
Cheresh,Chem. Abstract104:abstract No. 183980c (1986).
Yamada,Chem Abstract107:abstract No. 5066p (1987).
Poole,Chem Abstract105:abstract No. 169400c (1986).
Ruggeri et al.,Proc. Natl. Acad. Sci. USA83:5708-5712 (1986).
Ginsberg et al.,J. Biol. Chem.260:3931-3936 (1985).
Pierschbacher et al.,Proc. Natl. Acad. Sci. USA81:5985-5988 (1984).
Kloczewisk et al.,Biochemistry23:1767-1774 (1984).
Gartner and Bennett,J. Biol. Chem.260:11891-11894 (1985).
Kleffer and Phillips,Annu Rev. Cell Biol.36:329-357 (1990).
Plow et al.,Proc. Natl. Acad. Sci. USA82:8057-8061 (1985).
Pytela et al.,Proc. Natl. Acad. Sci. USA82:5766-5770 (1985).
Pytela et al.,Cell40:191-198 (1985).
Pytela et al.,Science231:1559-1562 (1985).
Gardner et al.,Cell42:439-448 (1985).
Pierschbacher et al.,Nature309:30-33 (1984).
D'Souza et al.,J. Biol. Chem.263:3943-3951 (1988).
Parise et al.,J. Biol. Chem.262:12597-12602 (1987).
Haskei et al.,Thromb. Res.56:687-695 (1988).
Plow et al.,Blood70:110-115 (1987).
Ruoslahti et al.,J. Clin. Invest.87:1-5 (1991).
Ali et al., Peptides Proc. 11th Amer. Peptide Symposium La Jolla, California, Marshall & Rivier, eds. Jul. 9-14, (1989).
Garsky, et al.,Proc. Natl. Acad. Sci. USA86:4022-4026 (1989).
Dennis et al.,Pro
Cheng Soan
Craig William S.
Lukeman David S.
Pierschbacher Michael D.
Tschopp Juerg F.
Borin Michael
Campbell & Flores LLP
La Jolla Cancer Research Foundation
LandOfFree
Method and composition for treating thrombosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for treating thrombosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treating thrombosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2912813